Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 17/20 | 0.46 |
| ▸ | CDK2 | P24941 | 17/20 | 0.46 |
| ▸ | CCND1 | P24385 | 14/20 | 0.46 |
| ▸ | CDK6 | Q00534 | 14/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.43 |
| ▸ | CDK9 | P50750 | 4/20 | 0.43 |
| ▸ | CDK4 | P11802 | 4/20 | 0.42 |
| ▸ | RB1 | P06400 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.42 |
| ▸ | CCND3 | P30281 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4149937 | 0.93 | MAPK8 (0.45) | CCNE1CDK2CCND1CDK6MAPK8 | |
| SCHEMBL3674910 | 0.87 | MAPK8 (0.51) | CCNE1CDK2CCND1CDK6MAPK8 | |
| SCHEMBL3669722 | 0.87 | MAPK8 (0.51) | CCNE1CDK2CCND1CDK6MAPK8 | |
| SCHEMBL3677669 | 0.83 | DPP7 (0.47) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL3673901 | 0.83 | MAPK8 (0.46) | CCNE1CDK2CCND1CDK6MAPK8 | |
| SCHEMBL3675022 | 0.82 | CCNE1 (0.46) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL3672761 | 0.81 | MAPK8 (0.45) | CCNE1CDK2CCND1CDK6MAPK8 | |
| SCHEMBL3682314 | 0.81 | MAPK8 (0.50) | CCNE1CDK2CCND1CDK6MAPK8 | |
| SCHEMBL3674101 | 0.81 | CCNE1 (0.46) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL3673904 | 0.80 | CCNE1 (0.46) | CCNE1CDK2CCND1CDK6CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004215-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004215-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | PDE4B, PDE4A, PDE3B | CCNE1 4327/4885CDK2 944/4885CCND1 4075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.